CORMEDIX INC (CRMD) Fundamental Analysis & Valuation

NASDAQ:CRMD • US21900C3088

Current stock price

7.42 USD
+0.09 (+1.23%)
At close:
7.4 USD
-0.02 (-0.27%)
After Hours:

This CRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CRMD Profitability Analysis

1.1 Basic Checks

  • In the past year CRMD was profitable.
  • In the past year CRMD had a positive cash flow from operations.
  • In the past 5 years CRMD reported 4 times negative net income.
  • In the past 5 years CRMD reported 4 times negative operating cash flow.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • CRMD has a Return On Assets of 19.74%. This is amongst the best in the industry. CRMD outperforms 97.38% of its industry peers.
  • CRMD has a Return On Equity of 40.23%. This is amongst the best in the industry. CRMD outperforms 97.38% of its industry peers.
  • CRMD has a Return On Invested Capital of 18.20%. This is amongst the best in the industry. CRMD outperforms 94.76% of its industry peers.
Industry RankSector Rank
ROA 19.74%
ROE 40.23%
ROIC 18.2%
ROA(3y)-17.27%
ROA(5y)-28.12%
ROE(3y)-15.67%
ROE(5y)-29.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400 -500

1.3 Margins

  • CRMD's Profit Margin of 52.31% is amongst the best of the industry. CRMD outperforms 97.38% of its industry peers.
  • CRMD has a Operating Margin of 48.17%. This is amongst the best in the industry. CRMD outperforms 99.48% of its industry peers.
  • Looking at the Gross Margin, with a value of 88.46%, CRMD belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRMD has grown nicely.
Industry RankSector Rank
OM 48.17%
PM (TTM) 52.31%
GM 88.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.06%
GM growth 5Y47.9%
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CRMD Health Analysis

2.1 Basic Checks

  • CRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • CRMD has more shares outstanding than it did 1 year ago.
  • CRMD has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CRMD has a worse debt to assets ratio.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.78, we must say that CRMD is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.78, CRMD perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
  • The Debt to FCF ratio of CRMD is 0.84, which is an excellent value as it means it would take CRMD, only 0.84 years of fcf income to pay off all of its debts.
  • CRMD has a Debt to FCF ratio of 0.84. This is amongst the best in the industry. CRMD outperforms 95.81% of its industry peers.
  • CRMD has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
  • CRMD has a worse Debt to Equity ratio (0.36) than 62.30% of its industry peers.
  • Although CRMD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 0.84
Altman-Z 1.78
ROIC/WACC2.04
WACC8.93%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • CRMD has a Current Ratio of 2.11. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
  • CRMD has a worse Current ratio (2.11) than 61.26% of its industry peers.
  • A Quick Ratio of 1.94 indicates that CRMD should not have too much problems paying its short term obligations.
  • CRMD has a Quick ratio of 1.94. This is comparable to the rest of the industry: CRMD outperforms 41.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.94
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CRMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 712.12% over the past year.
  • CRMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 617.03%.
  • CRMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 319.48% yearly.
EPS 1Y (TTM)712.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)617.03%
Revenue growth 3Y1545.19%
Revenue growth 5Y319.48%
Sales Q2Q%312.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.22% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 12.26% on average over the next years. This is quite good.
EPS Next Y-58.05%
EPS Next 2Y-41.67%
EPS Next 3Y-22.91%
EPS Next 5Y14.22%
Revenue Next Year-1.16%
Revenue Next 2Y-3.28%
Revenue Next 3Y3.93%
Revenue Next 5Y12.26%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M 800M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. CRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 3.67 indicates a rather cheap valuation of CRMD.
  • Based on the Price/Earnings ratio, CRMD is valued cheaper than 97.91% of the companies in the same industry.
  • CRMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.42.
  • Based on the Price/Forward Earnings ratio of 8.76, the valuation of CRMD can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 91.62% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.24, CRMD is valued rather cheaply.
Industry RankSector Rank
PE 3.67
Fwd PE 8.76
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 97.91% of the companies in the same industry are more expensive than CRMD, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 97.91% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.39
EV/EBITDA 3.48
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • CRMD has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as CRMD's earnings are expected to decrease with -22.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.67%
EPS Next 3Y-22.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRMD Dividend Analysis

5.1 Amount

  • No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRMD Fundamentals: All Metrics, Ratios and Statistics

CORMEDIX INC

NASDAQ:CRMD (4/24/2026, 8:00:01 PM)

After market: 7.4 -0.02 (-0.27%)

7.42

+0.09 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05
Earnings (Next)05-07
Inst Owners55.66%
Inst Owner Change-0.07%
Ins Owners7.98%
Ins Owner Change11.55%
Market Cap586.55M
Revenue(TTM)311.71M
Net Income(TTM)163.06M
Analysts83.08
Price Target14.86 (100.27%)
Short Float %21.7%
Short Ratio10.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.55%
Min EPS beat(2)-78.38%
Max EPS beat(2)91.47%
EPS beat(4)3
Avg EPS beat(4)21.25%
Min EPS beat(4)-78.38%
Max EPS beat(4)91.47%
EPS beat(8)7
Avg EPS beat(8)25.63%
EPS beat(12)8
Avg EPS beat(12)14.94%
EPS beat(16)11
Avg EPS beat(16)14.44%
Revenue beat(2)1
Avg Revenue beat(2)9.06%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)18.84%
Revenue beat(4)3
Avg Revenue beat(4)9.07%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)18.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.92%
PT rev (3m)-13.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.75%
EPS NY rev (1m)-37.74%
EPS NY rev (3m)-55.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.9%
Valuation
Industry RankSector Rank
PE 3.67
Fwd PE 8.76
P/S 1.88
P/FCF 3.39
P/OCF 3.35
P/B 1.45
P/tB N/A
EV/EBITDA 3.48
EPS(TTM)2.02
EY27.22%
EPS(NY)0.85
Fwd EY11.42%
FCF(TTM)2.19
FCFY29.46%
OCF(TTM)2.21
OCFY29.84%
SpS3.94
BVpS5.13
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.2654 (105.73%)
Profitability
Industry RankSector Rank
ROA 19.74%
ROE 40.23%
ROCE 23.03%
ROIC 18.2%
ROICexc 23.56%
ROICexgc 125.82%
OM 48.17%
PM (TTM) 52.31%
GM 88.46%
FCFM 55.43%
ROA(3y)-17.27%
ROA(5y)-28.12%
ROE(3y)-15.67%
ROE(5y)-29.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.06%
GM growth 5Y47.9%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 0.84
Debt/EBITDA 0.88
Cap/Depr 15.53%
Cap/Sales 0.73%
Interest Coverage 8831.82
Cash Conversion 106.29%
Profit Quality 105.97%
Current Ratio 2.11
Quick Ratio 1.94
Altman-Z 1.78
F-Score5
WACC8.93%
ROIC/WACC2.04
Cap/Depr(3y)171.72%
Cap/Depr(5y)634.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)712.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y-58.05%
EPS Next 2Y-41.67%
EPS Next 3Y-22.91%
EPS Next 5Y14.22%
Revenue 1Y (TTM)617.03%
Revenue growth 3Y1545.19%
Revenue growth 5Y319.48%
Sales Q2Q%312.11%
Revenue Next Year-1.16%
Revenue Next 2Y-3.28%
Revenue Next 3Y3.93%
Revenue Next 5Y12.26%
EBIT growth 1Y771.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y440.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y445.84%
OCF growth 3YN/A
OCF growth 5YN/A

CORMEDIX INC / CRMD Fundamental Analysis FAQ

What is the fundamental rating for CRMD stock?

ChartMill assigns a fundamental rating of 6 / 10 to CRMD.


Can you provide the valuation status for CORMEDIX INC?

ChartMill assigns a valuation rating of 8 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.


What is the profitability of CRMD stock?

CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.


What is the expected EPS growth for CORMEDIX INC (CRMD) stock?

The Earnings per Share (EPS) of CORMEDIX INC (CRMD) is expected to decline by -58.05% in the next year.